vs
GLOBUS MEDICAL INC（GMED）与RXO, Inc.（RXO）财务数据对比。点击上方公司名可切换其他公司
RXO, Inc.的季度营收约是GLOBUS MEDICAL INC的1.8倍（$1.5B vs $826.4M），GLOBUS MEDICAL INC净利率更高（17.0% vs -3.1%，领先20.1%），GLOBUS MEDICAL INC同比增速更快（25.7% vs -11.9%），GLOBUS MEDICAL INC自由现金流更多（$202.4M vs $-9.0M），过去两年RXO, Inc.的营收复合增速更高（26.8% vs 16.7%）
Globus Medical是总部位于美国宾夕法尼亚州奥杜邦的上市骨科医疗器械企业，专注于相关产品的设计、研发与商业化，助力外科医生为肌肉骨骼系统疾病患者提供治疗方案，促进患者康复。
RXO是总部位于美国的头部运输及物流解决方案供应商，核心业务覆盖货运经纪、大件商品最后一公里配送、运输管理服务与全链路供应链优化支持，主要服务北美制造业、零售业及电商领域的客户。
GMED vs RXO — 直观对比
营收规模更大
RXO
是对方的1.8倍
$826.4M
营收增速更快
GMED
高出37.6%
-11.9%
净利率更高
GMED
高出20.1%
-3.1%
自由现金流更多
GMED
多$211.4M
$-9.0M
两年增速更快
RXO
近两年复合增速
16.7%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $826.4M | $1.5B |
| 净利润 | $140.6M | $-46.0M |
| 毛利率 | 68.4% | — |
| 营业利润率 | 20.5% | -2.9% |
| 净利率 | 17.0% | -3.1% |
| 营收同比 | 25.7% | -11.9% |
| 净利润同比 | 430.4% | -84.0% |
| 每股收益（稀释后） | $1.01 | $-0.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收GMEDRXO
| Q4 25 | $826.4M | $1.5B | ||
| Q3 25 | $769.0M | $1.4B | ||
| Q2 25 | $745.3M | $1.4B | ||
| Q1 25 | $598.1M | $1.4B | ||
| Q4 24 | $657.3M | $1.7B | ||
| Q3 24 | $625.7M | $1.0B | ||
| Q2 24 | $629.7M | $930.0M | ||
| Q1 24 | $606.7M | $913.0M |
净利润GMEDRXO
| Q4 25 | $140.6M | $-46.0M | ||
| Q3 25 | $119.0M | $-14.0M | ||
| Q2 25 | $202.8M | $-9.0M | ||
| Q1 25 | $75.5M | $-31.0M | ||
| Q4 24 | $26.5M | $-25.0M | ||
| Q3 24 | $51.8M | $-243.0M | ||
| Q2 24 | $31.8M | $-7.0M | ||
| Q1 24 | $-7.1M | $-15.0M |
毛利率GMEDRXO
| Q4 25 | 68.4% | — | ||
| Q3 25 | 67.2% | — | ||
| Q2 25 | 66.6% | — | ||
| Q1 25 | 67.3% | — | ||
| Q4 24 | 59.9% | — | ||
| Q3 24 | 56.8% | — | ||
| Q2 24 | 58.7% | — | ||
| Q1 24 | 60.2% | — |
营业利润率GMEDRXO
| Q4 25 | 20.5% | -2.9% | ||
| Q3 25 | 17.9% | -0.5% | ||
| Q2 25 | 10.2% | — | ||
| Q1 25 | 16.2% | -2.1% | ||
| Q4 24 | 9.2% | -1.4% | ||
| Q3 24 | 7.7% | -1.9% | ||
| Q2 24 | 7.9% | — | ||
| Q1 24 | 1.3% | -1.3% |
净利率GMEDRXO
| Q4 25 | 17.0% | -3.1% | ||
| Q3 25 | 15.5% | -1.0% | ||
| Q2 25 | 27.2% | -0.6% | ||
| Q1 25 | 12.6% | -2.2% | ||
| Q4 24 | 4.0% | -1.5% | ||
| Q3 24 | 8.3% | -23.4% | ||
| Q2 24 | 5.0% | -0.8% | ||
| Q1 24 | -1.2% | -1.6% |
每股收益（稀释后）GMEDRXO
| Q4 25 | $1.01 | $-0.28 | ||
| Q3 25 | $0.88 | $-0.08 | ||
| Q2 25 | $1.49 | $-0.05 | ||
| Q1 25 | $0.54 | $-0.18 | ||
| Q4 24 | $0.19 | $-0.17 | ||
| Q3 24 | $0.38 | $-1.81 | ||
| Q2 24 | $0.23 | $-0.06 | ||
| Q1 24 | $-0.05 | $-0.13 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $557.2M | $17.0M |
| 总债务越低越好 | — | $387.0M |
| 股东权益账面价值 | $4.6B | $1.5B |
| 总资产 | $5.3B | $3.3B |
| 负债/权益比越低杠杆越低 | — | 0.25× |
8季度趋势，按日历期对齐
现金及短期投资GMEDRXO
| Q4 25 | $557.2M | $17.0M | ||
| Q3 25 | $18.8M | $25.0M | ||
| Q2 25 | — | $18.0M | ||
| Q1 25 | — | $16.0M | ||
| Q4 24 | $890.1M | $35.0M | ||
| Q3 24 | $71.9M | $55.0M | ||
| Q2 24 | $82.5M | $7.0M | ||
| Q1 24 | $80.4M | $7.0M |
总债务GMEDRXO
| Q4 25 | — | $387.0M | ||
| Q3 25 | — | $387.0M | ||
| Q2 25 | — | $387.0M | ||
| Q1 25 | — | $387.0M | ||
| Q4 24 | — | $351.0M | ||
| Q3 24 | — | $352.0M | ||
| Q2 24 | — | $370.0M | ||
| Q1 24 | — | $351.0M |
股东权益GMEDRXO
| Q4 25 | $4.6B | $1.5B | ||
| Q3 25 | $4.4B | $1.6B | ||
| Q2 25 | $4.3B | $1.6B | ||
| Q1 25 | $4.1B | $1.6B | ||
| Q4 24 | $4.2B | $1.6B | ||
| Q3 24 | $4.1B | $1.7B | ||
| Q2 24 | $4.0B | $579.0M | ||
| Q1 24 | $3.9B | $582.0M |
总资产GMEDRXO
| Q4 25 | $5.3B | $3.3B | ||
| Q3 25 | $5.1B | $3.2B | ||
| Q2 25 | $5.0B | $3.2B | ||
| Q1 25 | $4.7B | $3.3B | ||
| Q4 24 | $5.3B | $3.4B | ||
| Q3 24 | $5.1B | $3.4B | ||
| Q2 24 | $5.0B | $1.8B | ||
| Q1 24 | $4.9B | $1.8B |
负债/权益比GMEDRXO
| Q4 25 | — | 0.25× | ||
| Q3 25 | — | 0.24× | ||
| Q2 25 | — | 0.24× | ||
| Q1 25 | — | 0.24× | ||
| Q4 24 | — | 0.22× | ||
| Q3 24 | — | 0.21× | ||
| Q2 24 | — | 0.64× | ||
| Q1 24 | — | 0.60× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $248.6M | $7.0M |
| 自由现金流经营现金流 - 资本支出 | $202.4M | $-9.0M |
| 自由现金流率自由现金流/营收 | 24.5% | -0.6% |
| 资本支出强度资本支出/营收 | 5.6% | 1.1% |
| 现金转化率经营现金流/净利润 | 1.77× | — |
| 过去12个月自由现金流最近4个季度 | $588.8M | $-8.0M |
8季度趋势，按日历期对齐
经营现金流GMEDRXO
| Q4 25 | $248.6M | $7.0M | ||
| Q3 25 | $249.7M | $23.0M | ||
| Q2 25 | $77.9M | $23.0M | ||
| Q1 25 | $177.3M | $-2.0M | ||
| Q4 24 | $210.3M | $-7.0M | ||
| Q3 24 | $203.7M | $-7.0M | ||
| Q2 24 | $54.3M | $-5.0M | ||
| Q1 24 | $52.4M | $7.0M |
自由现金流GMEDRXO
| Q4 25 | $202.4M | $-9.0M | ||
| Q3 25 | $213.9M | $9.0M | ||
| Q2 25 | $31.3M | $9.0M | ||
| Q1 25 | $141.2M | $-17.0M | ||
| Q4 24 | $193.2M | $-19.0M | ||
| Q3 24 | $161.7M | $-18.0M | ||
| Q2 24 | $26.5M | $-16.0M | ||
| Q1 24 | $23.8M | $-4.0M |
自由现金流率GMEDRXO
| Q4 25 | 24.5% | -0.6% | ||
| Q3 25 | 27.8% | 0.6% | ||
| Q2 25 | 4.2% | 0.6% | ||
| Q1 25 | 23.6% | -1.2% | ||
| Q4 24 | 29.4% | -1.1% | ||
| Q3 24 | 25.8% | -1.7% | ||
| Q2 24 | 4.2% | -1.7% | ||
| Q1 24 | 3.9% | -0.4% |
资本支出强度GMEDRXO
| Q4 25 | 5.6% | 1.1% | ||
| Q3 25 | 4.7% | 1.0% | ||
| Q2 25 | 6.2% | 1.0% | ||
| Q1 25 | 6.0% | 1.0% | ||
| Q4 24 | 2.6% | 0.7% | ||
| Q3 24 | 6.7% | 1.1% | ||
| Q2 24 | 4.4% | 1.2% | ||
| Q1 24 | 4.7% | 1.2% |
现金转化率GMEDRXO
| Q4 25 | 1.77× | — | ||
| Q3 25 | 2.10× | — | ||
| Q2 25 | 0.38× | — | ||
| Q1 25 | 2.35× | — | ||
| Q4 24 | 7.94× | — | ||
| Q3 24 | 3.93× | — | ||
| Q2 24 | 1.71× | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
GMED
| Other | $391.8M | 47% |
| Nevro Merger Agreement | $293.6M | 36% |
| Enabling Technologies | $141.0M | 17% |
RXO
| Retail Sector | $546.0M | 37% |
| Last Mile | $298.0M | 20% |
| Food And Beverage Sector | $225.0M | 15% |
| Other Sector | $185.0M | 13% |
| Managed Transportation | $133.0M | 9% |
| Automotive Sector | $93.0M | 6% |
